文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌高剂量率近距离放疗:单日两次13.5 Gy方案的前瞻性毒性评估

High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.
PubMed 文献 · Radiother Oncol · 2018-04-03

该单中心前瞻性研究纳入119例低危(71%)或中危前列腺癌患者,采用单日内两次13.5 Gy高剂量率近距离放疗(HDR-BT)单药治疗,中位随访4.4年。结果显示无生化疾病证据率、总生存率和无转移生存率分别为96%、98%和98%,急性和晚期≥2级泌尿生殖毒性可控,未观察到≥4级毒性。

要点

  • 单日两次13.5 Gy HDR-BT单药治疗低中危前列腺癌安全有效。
  • 急性2级和3级泌尿生殖毒性累积发生率分别为9%和2%。
  • 晚期泌尿生殖毒性2级和1级发生率分别为18%和1%。

核心结论

  • HDR-BT 13.5 Gy×2作为单药治疗对低中危前列腺癌患者安全有效。

研究设计与样本

  • 2010年至2017年单中心前瞻性纳入119例低危(71%)或中危前列腺癌患者。
  • 患者接受单日内两次13.5 Gy HDR-BT,中位随访4.4年。

主要发现

  • 全组无生化疾病证据率、总生存率和无转移生存率分别为96%、98%和98%。
  • 急性2级和3级泌尿生殖毒性累积发生率分别为9%和2%。
  • 晚期泌尿生殖毒性2级和1级发生率分别为18%和1%。
  • 未检测到任何类型≥4级毒性。
  • 多因素分析显示较高IPSS(P=0.041)或较高V200(P=0.013)与任何级别急性泌尿生殖毒性风险增加相关。

临床怎么用

  • 对于低中危前列腺癌患者,可考虑单日两次13.5 Gy HDR-BT单药治疗方案。
  • 治疗计划中应关注V200和V150等剂量体积参数以降低急性泌尿生殖毒性风险。
  • 基线IPSS评分较高的患者应加强急性泌尿生殖毒性的监测与预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: High dose-rate (HDR) brachytherapy (BT) provides a highly conformal method of dose delivery to the prostate. The purpose of this study is to prospectively determine the toxicity of the treatment protocol of 13.5 Gy × 2 fractions. MATERIALS AND METHODS: From 2010 through 2017, 119 patients with low (71%) or intermediate-risk prostate cancer were prospectively treated in a single institute with HDR-BT at 13.5 Gy × 2 fractions within one day. Median follow-up time was 4.4 years. RESULTS: Actuarial rates of no biochemical evidence of disease, overall survival and metastasis-free survival for all patients were 96%,98% and 98%, respectively. The cumulative incidence of acute grade 2 and 3 genitourinary (GU) toxicity was 9% and 2%, respectively. The corresponding incidences of late GU toxicity were 18% and 1%. No grade ≥4 of either type of toxicity was detected. Multivariate analysis showed that having higher international prostate symptom score (IPSS; P = 0.041) or higher V200 (P = 0.013) was associated with a higher risk of experiencing any grade of acute GU toxicity. In addition, patients having a higher IPSS (P = 0.019) or a higher V150 (P = 0.033) were associated with a higher grade >1 acute GU toxicity. CONCLUSIONS: The findings of this study show that HDR-BT 13.5 Gy × 2 as monotherapy was safe and effective for prostate cancer patients with low-intermediate risk.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nagore G, Lopez Guerra JL, Krumina E, et al. High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions. Radiother Oncol. 2018. PMID: 29625808. doi:10.1016/j.radonc.2018.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。